Parameters Baseline 110 Months 122 Months

Table 1. Hormonal pattern before mitotane treatment and at 110 and 122 months follow-up*

615

0800 cortisol (nmol/L)

**midluteal phase

2400 cortisol	678	312	40.5	<50	
Cortisol after DXM	667	153	52.3	<50	
UFC (nmol/day)	1498	223	184	77-587	
08.00 ACTH (pg/ml)	6.4	7.2	10.2	7-51	
Aldosterone (pg/ml)	120	103		40-120	
DHEAS (mcg/ml)	2.24	0.2	0.4	1.1-4.7	
Androstenedione (ng/dl)	4.4	0.9	2.3	0.5-3.5	
E2 (ng/ml)	20	485**			
Progesterone	0.7	8.2**			
LH (mIU/L)	0.1	5.6**			
FSH (mIU/L)	0.8	3.1**			
*We performed laboratory evaluation	tion 45 days after the las	st lanreotide 30 mg i.m.	injection. Thyroxine the	erapy was not discontinued	

350

129

Normal Range

118-728

during the study. Impaired fasting glucose and glucose tolerance were diagnosed by an oral glucose (75g) tolerance test, (basal glucose

116 mg/dl, 120 min glucose 192 mg/dl).